Sino Biopharm, OrbiMed back Merck-partnered Akesobio's bet on made-in-China antibodies
In the latest boost for China’s flourishing antibody R&D scene, Merck-partnered Akesobio has bagged $150 million in Series D cash to push a slate of drugs targeting cancer, autoimmune disorders and even hyperlipidemia.
Akesobio’s lead drugs hit some well-established targets like PD-1, CTLA-4, IL12 and IL23. But its suite of in-house technologies — including the “Tetrabody” bispecific platform — sets it apart, according to the biotech.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.